What we think about Coherus BioSciences (CHRS)
Coherus in Three Words: Undervalued Niche Biotech
Discuss Coherus in our Community Forum
Background
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of novel immunotherapies to treat cancer. It recently commercialized Loqtorzi as a treatment for metastatic nasopharyngeal carcinoma and its pipeline is focused on developing other immunotherapies for cancer.
In December 2024, Coherus sold its Udenyca franchise to Intas Pharmaceutics for $558 million; which was a combination of $483 million upfront and $75 million from future milestones.
In June 2024, it sold its HUMIRA biosimilar drug Yusimry to Hong Kong King-Friend Industrial (HKF) for $40 million upfront.
Conviction Rating Changes
Coherus was downgraded from Buy to Potential Sell on March 11, 2025.